Oral Contraceptives, Hormone Replacement Therapy and Thrombosis

Summary

Oral contraceptives and hormone replacement therapy are used by hundreds of millions of women worldwide. Since the early 1960s it is known that female hormones increase the risk of venous thrombosis, myocardial infarction and stroke. This risk is still present with current low-dose oral contraceptives and, even though in absolute terms the risk is small, oral contraceptives form the major cause of thrombotic disease in young women. The risk is higher during the first year of use (up to 1 per 1000 per year), with the use of desogestrel- or gestodene-containing oral contraceptives (“third generation progestogens”) and among women with a prothrombotic predispositon. Hormone replacement therapy increases the risk of venous thrombosis, while results of randomised trials so far do not substantiate the expectation of a beneficial effect on the risk of arterial cardiovascular disease. First results are emerging that specific subgroups of women, with prothrombotic or other abnormalities, may be at risk, especially during the first years of use of hormone substitution.

Key words

Venous thrombosis - myocardial infarction - stroke - oestrogens - progestogens - oral contraceptives - hormone replacement therapy

• References

• 1 Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
• 2 Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forrier A, Dalen JE. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933-8.
• 3 Carter CJ. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 1994; 36: 423-38.
• 4 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton III LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159: 445-53.
• 5 Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N Engl J Med 1997; 337: 663-9.
• 6 Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich Jr J, Hobbins TE. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-5.
• 7 The Columbus Investigators.. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
• 8 Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, Ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-62.
• 9 Virchow R. Phlogose und Thrombose im Gefäßsystem; Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt: Staatsdruckerei; 1856
• 10 Jordan WM. Pulmonary embolism. Lancet 1961; i: 1146-7.
• 11 Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
• 12 Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopasusal oestrogens. Lancet 1996; 348: 981-3.
• 13 Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
• 14 The Coronary Drug Project Research Group.. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 1973; 226: 652-7.
• 15 van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-42.
• 16 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
• 17 World Health Organization.. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1582-8.
• 18 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
• 19 Vasilakis C, Jick H, Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610-1.
• 20 Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54: 5-13.
• 21 Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31: 56-63.
• 22 Haberlandt L. Über hormonale Sterilisierung des weiblichen Tierkörpers. Munich Med Wschr 1921; 68: 1577-8.
• 23 United Nations Department for Economic and Social Information and Policy Analysis Population Division. Levels and trends of contraceptive use as assessed in 1994. United Nations; New York: 1996
• 24 Records Unit and Research Advisory Service of the Royal College of General Practioners.. Oral contraception and thromboembolic disease. J R Coll Gen Pract 1967; 13: 267-79.
• 25 Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968; 2: 199-205.
• 26 Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. Br Med J 1969; 2: 651-7.
• 27 Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol 1969; 90: 365-80.
• 28 Boston Collaborative Drug Surveillance Program.. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease and breast tumours. Lancet 1973; i: 1399-404.
• 29 Porter JB. Oral contraceptives and nonfatal vascular disease –- recent experience. Obstet Gynecol 1982; 59: 299-302.
• 30 Royal College of General Practioners’ Oral Contraception Study.. Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract 1978; 28: 393-9.
• 31 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 1986; 292: 526.
• 32 Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 1995; 238: 31-7.
• 33 Inman WHW, Vessey MP. Investigation of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J 1968; 2: 193-9.
• 34 Lensing AW, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, Krekt J, Wouter TC, Huisman MV, Buller HR. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989; 320: 342-5.
• 35 Huisman MV, Buller HR, Ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 1986; 314: 823-8.
• 36 Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197-208.
• 37 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
• 38 Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48-52.
• 39 World Health Organization.. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-82.
• 40 Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low-oestrogen oral contraceptives. J Obst Gynecol 1995; 15: 195-200.
• 41 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93.
• 42 Rosendaal FR. Thrombosis in the young: epidemiology and risk factors, a focus on venous thrombosis. Thromb Haemost 1997; 78: 1-6.
• 43 Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. Br Med J 2000; 321: 1190-5.
• 44 Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-9.
• 45 Realini JP, Encarnacion CE, Chintapalli KN, Rees CR. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias. J Am Board Fam Pract 1997; 10: 315-21.
• 46 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Colly LP, Vandenbroucke JP. The association between oral contraceptives and venous thrombosis: the myth of the diagnostic suspicion- and referral bias. Arch Intern Med 1999; 159: 65-70.
• 47 Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7.
• 48 Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987; 69: 91-5.
• 49 Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research group on Oral Contraceptives and the Health of Young Women. Br Med J 1996; 312: 83-8.
• 50 Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 1998; 244: 27-32.
• 51 Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sørensen HT, Baech J, Gregersen H. Third generation oral contraceptives and heritable thrombophilia as risk factors for non-fatal venous thromboembolism. Thromb Haemost 1998; 79: 28-31.
• 52 Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79-83.
• 53 Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8.
• 54 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3.
• 55 Lidegaard Ø, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998; 57: 291-301.
• 56 Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.
• 57 Farmer RD, Todd JC, MacRae KD, Williams TJ, Lewis MA. Oral contraception was not associated with venous thromboembolic disease in recent study. Br Med J 1998; 316: 1090-1.
• 58 Vandenbroucke JP. Medical journals and the shaping of knowledge. Lancet 1998; 352: 2001-6.
• 59 Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. BMJ readers should know whose words they read. Br Med J 2000; 320: 381-2.
• 60 Vandenbrouke JP, Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives. BMJ 2000; 320: 57-8.
• 61 Spitzer WO. Thromboembolism and the pill: the saga must end. Human Reproduction 1998; 13: 1117-8.
• 62 Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. The pill and venous thromboembolism: a disarray of several layers of debate. Human Reproduction 1998; 13: 1119-20.
• 63 Spitzer WO. Balanced view of risks of oral contraceptive. Lancet 1997; 350: 1566-7.
• 64 Meirik O. Risks of oral contraceptives. Lancet 1998; 351: 521.
• 65 >Lidegaard Ø.. Oral contraceptives and venous thromboembolism: an epidemiological review. Eur J Contracept Reprod Health Care 1996; 1: 13-20.
• 66 Cramer DW. Safety of combined oral contraceptive pills. Lancet 1996; 347: 546-8.
• 67 Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-6.
• 68 Farmer RD, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database. Br Med J 2000; 321: 477-9.
• 69 Todd J, Lawrenson R, Farmer RD, Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database. Hum Reprod 1999; 14: 1500-5.
• 70 Weiss NS. Bias in studies of venous thromboembolism in relation to the use of new formulations of oral contraceptives. Contraception 1997; 55: 189-90.
• 71 Vandenbroucke JP, Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR. Risk of oral contraceptives and recency of market introduction. Contraception 1997; 55: 191-2.
• 72 Farley TM, Meirik O, Marmot MG, Chang CL, Poulter NR. Oral contraceptives and risk of venous thromboembolism: impact of duration of use. Contraception 1998; 57: 61-5.
• 73 Skegg DCG. Pitfalls of pharmacoepidemiology. Br Med J 2000; 321: 1171-2.
• 74 Skegg DCG. Third generation contraceptives: caution is still justified. BMJ 2000; 321: 190-1.
• 75 O’Brien PA. The third generation oral contraceptive controversy: The evidence shows they are less safe than second generation pills. Br Med J 1999; 319: 795-6.
• 76 Hannaford P. Science is not a dispassionate activity. Br Med J 2000; 320: 382.
• 77 Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177: 887-91.
• 78 Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57: 169-81.
• 79 Farley TMM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5: 721-35.
• 80 World Health Organization.. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific group. WHO Technical Report Series, no. 877. World Health Organization, 1998, Geneva.
• 81 Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129-40.
• 82 Jick H, Jick S, Myers MW, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 627-8.
• 83 World Health Organization.. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349: 1202-9.
• 84 Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, Thomas S, Mann R. Oral contraceptives and myocardial infarction: results of the MICA case-control study. Br Med J 1999; 318: 1579-84.
• 85 Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987; 157: 1042-8.
• 86 Stubblefield PG. Cardiovascular effects of oral contraceptives: a review. Int J Fertil 1989; 34 Suppl 40-9.
• 87 Rosing J, Tans G, Nicolaes GA, Thomassen MC, Van Oerle R, Van der Ploeg PM, Heijen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
• 88 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
• 89 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
• 90 Henkens CM, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
• 91 Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russo C. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
• 92 Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999; 354: 2036-40.
• 93 Middeldorp S, Meijers JCM, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Büller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
• 94 Meijers JCM, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 9-14.
• 95 Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JCM, Prins MH, Bouma BN, Büller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
• 96 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
• 97 Bellert FK, Ebert C. Effects of oral contraceptives on blood coagulation: a review. Obstet Gynecol Surv 1985; 40: 425-36.
• 98 Tans G, Rosendaal FR, Curvers J, Thomassen MCLGD, Bertina RM, Rosing J. APC-resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost 1999; 82: S202-3a (abstr).
• 99 Pabinger I, Schneider B. and the GTH study group. Thrombotic risk of women with hereditary antithrombin III-, protein C and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-52.
• 100 Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Buller HR, Wouter TC, Girolami A, Prins MH. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
• 101 Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-5.
• 102 Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-8.
• 103 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
• 104 Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487-90.
• 105 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 106 Kamphuisen PW, Eikenboom JCJ, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
• 107 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
• 108 Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82: 1024-7.
• 109 de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. Br Med J 1998; 316: 589-92.
• 110 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of the prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-7.
• 111 Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk and interaction. Semin Hematol 1997; 34: 171-87.
• 112 Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75: 524-5.
• 113 Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. Br Med J 1996; 313: 1127-30.
• 114 Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?. Thromb Haemost 1997; 78: 1480-3.
• 115 Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost 1995; 74: 928-32.
• 116 Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 1996; 76: 729-34.
• 117 World Heath Organization TFoOC.. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 1991; 98: 1117-28.
• 118 Meade TW, Haines AP, North WR, Chakrabarti R, Howarth DJ, Stirling Y. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet 1977; 2: 948-51.
• 119 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
• 120 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998; 80: 382-7.
• 121 Boyce J, Fawcett JW, Noall EWP. Coronary thrombosis and Conovid. Lancet 1963; i: 111.
• 122 Collaborative Group for the Study of Stroke in Young Women.. Oral contraception and increased risk of cerebral ischemia or thrombosis. N Engl J Med 1973; 288: 871-8.
• 123 World Health Organization.. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 498-505.
• 124 World Health Organization.. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 505-10.
• 125 Boston Collaborative Drug Surveillance program.. Surgically confirmed gallbladder disease, venous thromboembolism and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-9.
• 126 Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
• 127 Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet 1979; 2: 705-9.
• 128 Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195-8.
• 129 Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044-9.
• 130 Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, Longstreth Jr WT, Weiss NS, Wagner EH, Prentice R. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med 1993; 153: 1421-7.
• 131 Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA 1983; 249: 903-6.
• 132 Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; 1: 858-60.
• 133 Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 53: 277-81.
• 134 Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol 1993; 82: 1021-8.
• 135 Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women’s characteristics. J Clin Epidemiol 1993; 46: 211-9.
• 136 Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?. Br Med J 1994; 308: 1268-9.
• 137 Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy – results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7.
• 138 Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9.
• 139 Devor M, Barrett-Connor E, Renvall M, Feigal Jr D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82.
• 140 Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150-4.
• 141 Young RL, Goepfert AR, Goldzieher HW. Estrogen replacement therapy is not conducive of venous thromboembolism. Maturitas 1991; 13: 189-92.
• 142 Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 1027.
• 143 Varas Lorenzo C, Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 147: 387-90.
• 144 Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997; 314: 796-800.
• 145 Grady D, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997; 278: 477.
• 146 Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghoke D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 2000; 132: 689-96.
• 147 Høibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism – a population-based case-control study. Thromb Haemost 1999; 82: 1218-21.
• 148 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. for the Heart and estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
• 149 The Women’s Health Initiative Investigators.. Design of the Women’s Health Initiative Clinical Trial and Observational Study. Controlled Clin Trials 1998; 19: 61-109.
• 150 Larkin M. Ups and downs for HRT and heart disease. Lancet 2000; 355: 1338.
• 151 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
• 152 Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-5.
• 153 Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, Lacroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident non-fatal myocardial infarction. JAMA 2001; 285: 906-13.
• 154 The Writing Group for the PEPI Trial.. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208.
• 155 Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-22.
• 156 Scarabin PY, Alhenc-Gelas M, Oger E, Plu-Bureau G. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women – a randomised controlled trial. Thromb Haemost 1999; 81: 673-5.
• 157 Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, Peverill RE. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404-9.
• 158 Koh KK, Horne III MK, Cannon III RO. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost 1999; 82: 626-33.
• 159 Douketis JD, Gordon M, Johnston M, Julian JA, Adachi JR, Ginsberg JS. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res 2000; 99: 25-34.
• 160 Lowe GDO, Upton MN, Rumley A, McConnachie A, O’Reilly DSJ, Watt GCM. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, tPA, PAI and C-reactive protein: a cross-sectional population survey. Thromb Haemost. 2001 (in press).
• 161 Greenblatt DJ. A retrospective case-control study of diseases associated with oral contraceptive use. Am Heart J 1975; 89: 677-8.
• 162 Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol 1978; 108: 480-5.
• 163 Maguire MG, Tonascia JA, Sartwell PE, Stolley PD, Tockman MS. Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol 1979; 110: 188-95.
• 164 World Health Organization.. Cardiovascular disease and use of oral contraceptives. WHO Bulletin OMS 1989; 67: 417-23.
• 165 Grounds M. Anovulants: thrombosis and other associated changes. Med J Aust 1974; 2: 440-6.
• 166 Diddle AW, Gardner WMH, Williamson PH, Johnson JR, Hemphill JL, Godwin CW. Oral contraceptives steroids and thrombophlebitis. J Tenn Med Assoc 1978; 71: 22-6.
• 167 Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and non-fatal vascular disease. Obstet Gynecol 1985; 66: 1-4.
• 168 Fuertes de la Haba A, Curet JO, Pelegrina I, Bangdiwala I. Thrombophlebitis among oral and nonoral contraceptive users. Obstet Gynecol 1971; 38: 259-63.
• 169 Walker AM, Martin-Moreno JM, Artalejo FR. Odd man out: a graphical approach to meta-analysis. Am J Public Health 1988; 78: 961-6.